Historically characterized by excessive daytime sleepiness and cataplexy, narcolepsy is increasingly recognized as a ...
Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds ...
Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a ...
EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.
Tebipenem pivoxil becomes the only FDA-approved oral carbapenem for complicated UTIs/pyelonephritis in adults lacking viable ...
Maintenance revumenib was restarted post SCT at the pretransplant dose with azole-based adjustments across monotherapy, combination-trial, and expanded-access settings in genetically defined ...
Prolonged follow-up showed superior PFS with mosun-pola versus R-GemOx in the overall SUNMO population (HR, 0.41) alongside ...
Salma Patel, MD, shares findings from the implementation of combination therapy recommendations for patients with chronic ...
Standardized order sets, clinical team training on toxicity grading and treatment algorithms, and immediate access to ...
Alexander Spira, MD, PhD, medical oncologist at Virginia Cancer Specialists and chief scientific officer of NEXT Oncology, ...
Three persistent barriers are preventing patients with obstructive sleep apnea (OSA) from receiving timely diagnosis and ...
Walcker will oversee enterprise strategy, operations, and growth at The Specialty Alliance, while James Weber, MD, focuses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results